Dorsey & Whitney Trust CO LLC Sells 773 Shares of Takeda Pharmaceutical Company Limited (NYSE:TAK)

Dorsey & Whitney Trust CO LLC cut its stake in Takeda Pharmaceutical Company Limited (NYSE:TAK) by 4.7% in the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 15,549 shares of the company’s stock after selling 773 shares during the quarter. Dorsey & Whitney Trust CO LLC’s holdings in Takeda Pharmaceutical were worth $206,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of the stock. Versant Capital Management Inc purchased a new position in shares of Takeda Pharmaceutical during the fourth quarter valued at about $26,000. Wilmington Savings Fund Society FSB bought a new stake in Takeda Pharmaceutical during the 3rd quarter valued at approximately $40,000. BNP Paribas Financial Markets grew its holdings in shares of Takeda Pharmaceutical by 416.0% during the 3rd quarter. BNP Paribas Financial Markets now owns 3,220 shares of the company’s stock worth $46,000 after acquiring an additional 2,596 shares during the period. Smithfield Trust Co raised its position in shares of Takeda Pharmaceutical by 76.9% in the 3rd quarter. Smithfield Trust Co now owns 3,428 shares of the company’s stock worth $49,000 after acquiring an additional 1,490 shares in the last quarter. Finally, Erste Asset Management GmbH purchased a new position in shares of Takeda Pharmaceutical in the 3rd quarter valued at approximately $52,000. 9.17% of the stock is owned by hedge funds and other institutional investors.

Takeda Pharmaceutical Trading Down 1.0 %

NYSE TAK opened at $14.90 on Wednesday. The stock’s 50 day moving average is $13.66 and its 200 day moving average is $13.90. The company has a quick ratio of 0.72, a current ratio of 1.31 and a debt-to-equity ratio of 0.63. The firm has a market capitalization of $47.39 billion, a PE ratio of 37.24, a P/E/G ratio of 0.24 and a beta of 0.46. Takeda Pharmaceutical Company Limited has a twelve month low of $12.57 and a twelve month high of $15.22.

Takeda Pharmaceutical (NYSE:TAK) last released its earnings results on Thursday, January 30th. The company reported $0.42 earnings per share for the quarter, topping analysts’ consensus estimates of $0.34 by $0.08. Takeda Pharmaceutical had a net margin of 4.53% and a return on equity of 9.39%. Research analysts forecast that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

About Takeda Pharmaceutical

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.